Oculis (OCS) Q3 2026 earnings review
Oculis buys full rights to nerve drug, while staff costs rise
Oculis, a Swiss developer of treatments for eye and nerve diseases, spent more on staff while outside trial bills fell. Quarterly operating loss widened 16% from a year ago to CHF 24 million as payroll and stock compensation rose, offsetting lower contractor bills after its diabetic eye trials ended. Non-cash warrant and currency gains narrowed the headline net loss to CHF 18 million, and the group finished September with CHF 210 million in cash and short-term investments.
| Operating loss | CHF 23.6M +16% from a year ago |
|---|---|
| Total personnel expenses | CHF 12.1M +40% from a year ago |
| Cash and short-term investments | CHF 210.3M +45% from a year ago |
| 12-month cash runway outlook | Unchanged covers obligations for at least 12 months |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because locking up full ownership of its main nerve drug offsets the rising cost of its workforce and share dilution. Buying worldwide rights to Privosegtor from Accure Therapeutics for $4 million in cash and up to 2 million shares removes future license payouts and adds multiple sclerosis as a new target. The caution: management renewed an equity sales program for up to $125 million while administrative and research staff costs now consume more than half of quarterly spending.
The question now is whether late-stage trial results for dry-eye drug Licaminlimab and optic nerve candidate Privosegtor will justify the heavier payroll and rising share count. Positive data would support a commercial launch using its CHF 75 million credit line, while a clinical setback would leave shareholders diluted after May's diabetic eye trial failure. Upcoming trial readouts and the closing of the Accure acquisition will decide.
🐂 Bull Case
Buyout of Privosegtor Rights Removes Future License Obligations
Privosegtor is Oculis's main experimental drug for protecting optic nerves from damage, which the Swiss eye-care biotechnology company previously held under a license from Accure Therapeutics. Following the failure of its legacy diabetic eye drop in May 2026, management made Privosegtor and its dry-eye candidate Licaminlimab the center of the pipeline.
On August 10, 2026, Oculis signed an agreement with Accure "to acquire all of Accure’s worldwide development and commercial rights to Privosegtor" and terminate the old license. The deal also includes ACT-02, "an early-stage preclinical neurology drug candidate", and supports plans for a US regulatory filing "for the treatment of acute multiple sclerosis (“ MS ”) relapses".
- Up-front cash payment: $3.8 million (CHF 3.2 million) upon closing
- Equity consideration: up to 2,050,000 Oculis ordinary shares, split between locked-up shares and milestone shares
- Share lockup period: up to two years following completion of the transaction
Buying the rights outright matters because it eliminates future license obligations to Accure before late-stage optic nerve trials finish. Because most of the price is paid in stock tied to milestones, the group preserves its cash for clinical studies.
What to watch: formal closing of the Accure acquisition and the final accounting breakdown in the full-year report. Closing the purchase will confirm Oculis owns full worldwide rights before late-stage trial readouts arrive.
Cash Reserves and Credit Lines Fund Late-Stage Trials
As a clinical-stage drug developer with no commercial product sales, the Swiss biotechnology group relies on its balance sheet to pay for multi-year patient studies. The board stated that the business "has the ability to meet its financial obligations for at least the next 12 months".
By our math, Oculis ended September with CHF 210.3 million in combined cash and short-term financial assets, up 44.8% from CHF 145.2 million a year earlier. In the third quarter, operating cash outflow was CHF 19.0 million by our math, as the group did not sell any new shares under its equity program during those three months.
In addition to its cash on hand, the drugmaker holds an undrawn loan facility with BlackRock's Kreos Capital worth up to CHF 75.0 million, expandable to CHF 100.0 million. At the current quarterly cash burn of CHF 19.0 million, existing cash alone covers nearly 11 quarters of operations.
What to watch: quarterly operating cash outflow in the fourth quarter as the three PIONEER optic nerve trials enroll patients. A steady burn rate near CHF 19 million would preserve the multi-year cash cushion without drawing debt.
Winding Down Eye Drop Trials Cut Contractor Bills
External service providers are outside clinical research contractors that run hospital trials for Oculis. The drugmaker noted that "the OCS-01 DIAMOND-1 and DIAMOND-2 trials in diabetic macular edema were completed during the second quarter of 2026" after missing their primary goal.
Stopping work on that diabetic eye program lowered outside research bills by 11.3% from a year ago to CHF 7.9 million in the third quarter. Over the first nine months of 2026, external research contractor spending fell 15.6% by our math, dropping from CHF 28.8 million to CHF 24.3 million.
Those contractor savings kept total research and development spending growth down at 6.6% for the quarter, which freed up budget for the Privosegtor optic nerve studies and the Licaminlimab dry-eye trial. What to watch: external research contractor expenses in the fourth quarter, where a rebound above CHF 9 million would show late-stage optic nerve enrollment is picking up speed.
🐻 Bear Case
Staff Costs Push Quarterly Operating Burn Higher
Even though outside clinical contractor bills dropped, total operating expenses rose 15.1% from a year ago to CHF 23.6 million, widening the quarterly operating loss by 16.5% to CHF 23.6 million. Oculis stated that higher staff costs were "related to increased pipeline development and corporate activities".
- Total personnel expenses: CHF 12.1 million in Q3, up 39.9% from CHF 8.6 million a year ago
- Share-based compensation: CHF 6.7 million, up 47.3% from a year ago
- Cash payroll and related expenses: CHF 5.4 million, up 31.7% from a year ago
- General and administrative expenses: CHF 8.6 million, up 33.8% from a year ago
This shift matters because personnel expenses now account for 51.1% of total operating spending by our math, up from 42.0% a year earlier. Unlike outside clinical trial contracts that wind down when a study finishes, internal salaries and administrative overhead represent a fixed cost base.
What to watch: general and administrative cash payroll in the fourth-quarter report. Another increase above 30% from a year ago would mean corporate overhead is consuming cash meant for clinical trials.
Ongoing Share Sales and Deal Grants Dilute Shareholders
Oculis funds its clinical trials primarily by issuing new ordinary shares. On November 3, 2026, management signed an amended sales agreement with Leerink Partners to renew its at-the-market equity program for "an aggregate offering price of up to $125 million through the ATM Program".
By our math, issued shares excluding treasury stock grew 18.2% over the past year, climbing from 52.4 million to 61.9 million shares. During the first half of 2026, the Swiss drugmaker created 7.75 million treasury shares and sold 2.25 million of them for CHF 47.8 million ($61.3 million), leaving 6.2 million treasury shares ready for sale.
Adding up to 2.05 million shares for the Accure deal and CHF 18.4 million of nine-month employee stock compensation means existing shareholders face steady dilution before any drug reaches the market. What to watch: share issuances under the renewed $125 million ATM program in the fourth quarter, as rapid sales would reduce each share's claim on future drug royalties.
Non-Cash Accounting Gains Masked the Wider Operating Loss
On the bottom line, Oculis reported that its basic loss per share narrowed from CHF 0.32 a year ago to CHF 0.30 in the third quarter, while nine-month net loss dropped from CHF 75.4 million to CHF 57.1 million. Those headline figures suggest the business is reducing its losses.
In reality, non-operating finance items drove the improvement. In the third quarter, the group recorded a CHF 3.2 million non-cash accounting gain from revaluing warrant liabilities and a CHF 2.0 million currency gain on US dollar balances. Stripping out those two items, the loss widened 16.5% by our math to CHF 23.3 million.
The per-share loss only shrank because a larger share count spread the loss across more shares. What to watch: operating loss before finance items in the fourth quarter, which will show the true cost of running the trials without warrant revaluation swings.
👓 Other Themes
Stronger US Dollar Lifted Cash Valuation
Oculis reports its financial statements in Swiss francs but holds a large share of its cash and short-term investments in US dollars. Favorable movements of the US dollar against the Swiss franc generated foreign currency exchange gains of CHF 2.0 million in the third quarter and CHF 3.7 million over the first nine months of 2026, reversing a CHF 6.2 million currency loss in the prior-year period.
💲 Other KPIs
Fell 31.2% from CHF 20.0 million at the end of 2025. Accrued expenses are bills owed to clinical trial contractors and staff for work already performed. Paying down bills from the completed diabetic eye trials drove the CHF 5.7 million working capital cash outflow over the first nine months.
Dropped 67.8% from CHF 14.5 million at the end of 2025, and down from CHF 7.8 million in the second quarter. Warrant liabilities represent the accounting value of rights held by investors to buy Oculis shares at a fixed price. Warrant exercises and downward fair value adjustments of CHF 7.3 million reduced the balance.
Quarterly grant income fell 97.1% from CHF 243 thousand a year ago and down from CHF 310 thousand in the second quarter. This income comes from research tax credits awarded by the Icelandic government to the group's local subsidiary, lifting the unpaid accrued income balance on the balance sheet to CHF 1.6 million.
🔮 Guidance
Unchanged. The board repeated its standard accounting statement that current cash and short-term investments of CHF 210.3 million cover obligations for at least the next year. By our math, at the third-quarter operating cash burn of CHF 19.0 million, existing cash reserves would last nearly 11 quarters, or into 2029.
❓ Key Questions
Is the Licaminlimab dry-eye readout still on track for Q4?
Earlier in 2026, management targeted fourth-quarter 2026 results for the PREDICT-1 registrational trial of Licaminlimab in dry eye disease. The third-quarter financial statements did not mention the readout timing.
When will the Accure acquisition close and on what terms?
Oculis signed the agreement to buy Privosegtor rights on August 10, 2026, for $3.8 million in cash and up to 2.05 million shares, but the deal had not closed by November 3. Investors do not know the split between up-front shares and milestone shares.
Why is administrative payroll growing faster than research spending?
General and administrative expenses rose 33.8% from a year ago in the third quarter while research and development grew only 6.6%. Management has not explained when corporate hiring will level off.
When will Oculis file the multiple sclerosis application for Privosegtor?
The corporate note highlights plans for an Investigational New Drug application with US regulators to test Privosegtor in acute multiple sclerosis relapses, but gives no target quarter for the submission.